Biocytogen and Merck to advance antibody-conjugated lipid-based delivery solutions
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Subscribe To Our Newsletter & Stay Updated